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In light of the World Anti Doping Agency’s 2013 Code Revision process, we critically explore the applicability of two
of three criteria used to determine whether a method or substance should be considered for their Prohibited List,
namely its (potential) performance enhancing effects and its (potential) risk to the health of the athlete. To do so,
we compare two communities of human guinea pigs: (i) individuals who make a living out of serial participation in
Phase 1 pharmacology trials; and (ii) elite athletes who engage in what is effectively ‘unregulated clinical research’
by using untested prohibited or non-prohibited performance enhancing substances and methods, alone or in
combination. Our comparison sheds light on norms of research ethics that these practices exacerbate with respect
to the concepts of multiplicity, visibility, and consistency. We argue for the need to establish a proper governance
framework to increase the accountability of these unregulated research practices in order to protect the human
guinea pigs in elite sports contexts, and to establish reasonable grounds for the performance enhancing effects,
and the risks to the health of the athlete, of the methods and substances that might justify their inclusion on
the Prohibited List.
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Nearly 25 years ago, von Ammon and Wettstein asserted
that “Bioethics has paid little attention to the issues raised
by health and medical care in athletic competition” [1].
While there has been recent discussions of this nexus, the
situation has not developed far [2,3]. In this paper we wish
to help to redress this tendency of the bioethical discourse,
and address a critical but neglected issue at the intersec-
tion of medical ethics and sport ethics: how performance
enhancing technologies are introduced in competitive ath-
letics, and what implications they have on the athletes-
subjects. We argue that the introduction of performance
enhancing technologies in the practice of professional
sports amounts to unregulated clinical research, and that* Correspondence: silvia.camporesi@kcl.ac.uk
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We position our discussion in relation to other problem-
atic practices of participation in research, such as healthy
individuals who make a living out of serial participation in
Phase 1 trials in the pharmaceutical research context. Our
analysis points to the exacerbations of classical problems
of research ethics when translated to the professional
sports context and the pharmaceutical research context,
and to the necessity of establishing a proper framework
for research on performance enhancing agents.Athletes as guinea pigs?
Elite sport is an arena where sports medicine and sports
science teams have been keen to exploit biomedical and
biotechnological innovations regarding injury, treatment
of injury and health optimization, irrespective of the
epistemic support for their practices. The motivational
force of elite sports status has led to the proliferation ofoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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leading sports medicine experts to wonder whether
the field has more than its fair share of “snake oil” sales-
men [4]. Examples range from the more to less credible,
and include the use of platelet rich plasma to enhance
recovery (despite its disputed evidence base) [5], or
pre-emptive surgery (as in Tommy John elbow tendon
replacement mistakenly thought to enhance baseball
pitching performance by eager excessively enthusiastic
parents) [6]. More recent discussion includes examples
of athletes who might experiment with the latest gener-
ation of gene transfer techniques to enhance their per-
formances [7].
Given the power-saturated contexts of elite sport, ath-
letes often find themselves vulnerable actors in the
nexus of networks between sport and medicine [8]. To
the best of our knowledge, King and Robeson (2007)
were the first to highlight the problematic issue of how
the introduction of broadly conceived performance en-
hancing technologies in competitive athletics constitutes
unregulated clinical research [8]. King and Robeson
comment on their position at the cutting edge of science
and technology defining athletes as “unwitting or unwill-
ing research subjects”, or “guinea pigs” ([8], p.1). They
note how well understood problems in research ethics
(i.e. vulnerability, voluntariness, undue influence, full
disclosure, equitable subject selections, conflict of inter-
est) become particularly problematic in the professional
sports context, as opposed to the more typical health,
medical and scientific contexts in and through which re-
search is already governed.
In addition, the athletes-guinea pigs lack protection
against the conflict of interest that can arise when the
individual’s long-term health is not the goal of the inno-
vations being introduced in the professional sport con-
text, despite the presence of idealized statements in key
medical pronouncements such as the International
Olympic Committee’s 2009 Medical Code [9]. Quite to
the contrary, short-term gains and the gaining of ‘com-
petitive edge’ are often in conflict with the long-term
health of the athlete-subject [10-12].
In this essay we build on the analysis by King and
Robeson, and apply the foil of Italian essayist Italo Calvino
[13] to analyse the ethical issues of current modes of
research participation. To this end we compare the two
communities of human guinea pigs, whose juxtaposition
helps bring into focus problematic issues in both prac-
tices. In his collection of essays “Six memos for the next
millennium”, Calvino spelled out six ‘values’ or qualities
that he thought it was important to preserve in the tran-
sition to the next millennium: lightness, quickness,
exactitude, multiplicity, visibility, and consistency [13].
For Calvino, these values pertained to the realm of lit-
erature and writing, but their value and significanceneed not be thus limited. In particular, three of these
six values analysed by Calvino, namely visibility, multi-
plicity, and consistency seem particularly apposite to
our analysis of contemporary practices of participation
in research in professional sport and pharmaceutical re-
search, and it is through these lenses that we will carry
out our ethical analysis.
Visibility
For Calvino, each lecture (or ‘Memo’ as he put it) was to
be devoted to the analysis of one indispensable literary
value. Visibility dealt with the imaginative process, and
was regarded by Calvino as a fundamental value, as it
allowed readers to ‘see things’, and to see the process
through which that new seeing was enabled. In the con-
text we analyse here, we understand ‘visibility’ to mean
two things: a) the level of information that individuals
have access to in regard to the kind of drugs or pharma-
ceuticals they are being administered, or the regimes or
surgeries they undergo; and b) the level of transparency,
and thereby accountability, that characterizes the profes-
sional sport context.
Athletes lack information on the safety and effective-
ness of the agents that they are taking, or of the per-
formance enhancing technologies (e.g. injury prevention,
training schedules, post-trauma surgeries) that they are
subjected to. As a matter of fact, in the current system
where innovations are translated directly into athletics
amounting to ‘unregulated clinical research’ ([8], p.1),
the safety and effectiveness of the agents and methods
cannot be adequately determined. The lack of informa-
tion means that, in some cases, athletes take risks with-
out experiencing any benefit. This happens because the
WADA CODE does not require that a substance have a
demonstrably performance-enhancing effect for it to be
included on the Prohibited List, making the rational un-
derpinnings of the decision to have a substance enter
the List or not somewhat opaque. At present, it suffices
that the substance has the ‘potential’ to enhance athletic
performance, in addition to meeting one of the other
two criteria of the definition of doping: that it is harmful
(or potentially so), or that it is against the spirit of sport
[14]. We will discuss the WADA CODE and its criteria
more in detail in Section The need for research on
enhancements.
There is also a further sense in which the visibility of
athlete guinea-pigs in the elite sports community is very
limited: the data on safety and efficacy does not see the
light of day in scientific journals, or does so in – one
suspects – anodyne form and only after competitive ad-
vantage is not compromised. The opacity surrounding
the science and medicine of elite sports is problematic
since individuals and sport science teams do not wel-
come external scrutiny. Thus, complete transparency of
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of sports science and technology support systems. A lack
of transparency clouds the appreciation of lines of ac-
countability, as we discuss in the case of Birgit Dressel
below. Complete transparency of course undermines
competitive advantage.
Multiplicity
In literature, multiplicity refers to the infinite possibilities
of intertwined reality and fiction open to humankind, in a
kind of Russian doll multiplication of possibilities that
we find in the works of Jorge Luis Borges, Carlo Emilio
Gadda, and Calvino himself, among others. Multiplicity is
a hidden feature of the world. While reality can of course
be read as having a single layer of meaning, the discovery
of hidden strata of significance demands an attentive in-
terpreter of the world. In the context of professional sport
and pharmaceutical research, multiplicity becomes also a
central feature from the perspective of the subjects. In the
context of pharmaceutical research, ‘volunteers’ participate
in more than one Phase 1 trial at a time, and are being ad-
ministered a cocktail of drugs, as we discuss in Section Hu-
man guinea pigs in the pharmaceutical industry. In both
cases, the multiple drugs being administered have n-
possible combinations of interactions, the result of which
is difficult, if not impossible, to predict.
German heptathlete Birgitt Dressel is an example of
high dosage polypharmacy doping, or what we shall refer
to after Calvino as “pharmaceutical multiplicity”. Birgit
Dressel was born in Bremen, West Germany, in 1960.
She came in ninth at the 1984 Olympic Games in Los
Angeles, and fourth at the 1986 European Champion-
ships in Stuttgart, West Germany. She died on April 10,
1987 due to multiple organ failure caused by the com-
bination of pharmaceuticals she had been ingesting over
the past months aiming to enhance her athletic perform-
ance [15]. In response to her mother’s anxieties, Dressel
is reported to have said “These are all harmless drugs.
All athletes take them. It's really nothing special” [16].
An autopsy revealed traces of 101 different medications
in her body including bovine tissue [17]. The investiga-
tion report on her death concludes that despite her
powerful appearance Birgit Dressel was the opposite of a
healthy person: as reported in the German newspaper
‘Der Spiegel”, Dressel was “in truth a chronically sick
young woman [emphasis added] pumped full with hun-
dreds of drugs. Sport had made a cripple of her long
ago, destroying her joints and ruining her internal or-
gans prematurely” [18].
What is widely believed to be a further case of such
pharmaceutical multiplicity is American track and field
athlete Florence Griffith Joyner (Flo Jo as she was ubi-
quitously known) (1959–1998), who was known as the
‘fastest woman of all time’, and whose career was doggedby rumours of drug abuses which linger even today as
the causes of her premature death at 38 years old. Her
autopsy, while not being conclusive as to the causes of
her death, revealed the presence of a cocktail of drugs
in her body [19]. Less dramatically, several of Lance
Armstrong’s past professional cycling entourage have
reported use of human growth hormones, testosterone
and erythropoietin in combination [20]. The professional
cycling world has been one of the athletic contexts
where doping practices are most widespread, but the
possibility of widespread multi-product doping is a rea-
sonable assumption in some, though not all, sports,
where athletes participating in doping practices expect
to obtain ‘enhancement benefits’ that would provide
them with the competitive edge they are looking for to
beat competitors, along with such extrinsic benefits
(prize money, media profile, sponsorship, etc.) as come
in train. Figure 1 illustrates the combination of drugs
that a professional cyclist declared to be taking at a drug
control visit (note that this quite extensive list accounts
only for the drugs that he declared himself to be taking).
The combination of these substances, and those (if
any) not declared, along with the extraordinary training
schedules that athletes engage with, will bring about ef-
fects that cannot be fully understood nor controlled by
those in the sports medical entourage. This fact is exac-
erbated as the data on the ‘potential’ performance-
enhancing effect of an agent are currently extrapolated
from clinical trials conducted with therapeutic purposes,
on a pool of subjects that has little in common with the
population that will eventually be prescribed the drug
(see Section The need for research on enhancements for
a discussion of the problem of ‘externality’).
Consistency
‘Consistency’ was to be the sixth and final lecture that
Calvino prepared for his visiting professorship at Har-
vard, but that unfortunately he could not deliver due to
his sudden and premature death in 1985. Here, we
understand ‘consistency’ in respect to the supposed in-
tegrity of sports, which athletes who engage in doping
practices are said to be jeopardizing. WADA claims
that: “In all of WADA’s work and the fulfillment of its
Strategic Objectives, it will: preserve the integrity and
value of sport and youth” [21]. Indeed, one of the three
defeasible WADA criteria for a product or process to
be considered for the Prohibited List is that it violates
“the spirit of sport” [14]. How should we understand
this claim?
In the contexts of professional sport, what threatens
their integrity is the notion of something like a victor
who has been tested in sufficiently similar ways with re-
course to sufficiently similar modes of preparation and
training [22]. Sports enshrine formal equality; once
Figure 1 Anonymised combination of drugs declared by a professional cyclist at a drug control. Courtesy of UCI.
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mit to the same constitutive and regulative framework
[23]. Fairness requirements in particular must be satis-
fied, though these are sometimes more discretionary
(such as the size of the playing roster, the budget for the
team, the drafting process, and so on [22]). Anti-doping
policy is not, however, discretionary in this way. In want-
ing the best athlete or team to win, we understand that
part of what “best” means is that the athletes or teams
submit themselves to the formal and informal rules of
their sport, and excellence within that framework. Con-
sidered analogically, if sports were to be understood as
athletic experiments [24], then they should not be con-
taminated by extraneous variables (such as excessive
luck, bribery and corruption, incompetent officiating, or
judging, and so on). Doping, given the existence of glo-
bal anti-doping policy, thus represents a perversion of
athletic talent and a contamination of the integrity of
the contest. Of course the analogy should not be pressed
too hard. Luck, for example, is an element of all sport,
though we can recognise how an excess of it can gift a
lesser opponent a pyrrhic victory. Nor can one entirely
equalize pre-competition support (whether scientific or
economic). Nonetheless, sports legislators make consid-
erable efforts to maintain the integrity of sports under-
stood as the provision of an equitably balanced
competition where there is fair opportunity for uncer-
tainty of outcome to be a reasonable proposition. This is
precisely what doping, though not exclusively, usurps or
contaminates.We cannot discuss here at length the objections to
WADA retaining the ‘spirit of sport’ criterion in the re-
vised 2015 Code. It is frequently the target of an unsus-
tainable objection that it is in principle conceptually
vague – and therefore more open to abuse – than the
performance enhancing and harm to health criteria. Not
only does this objection fall foul of anti-essentialist
philosophical objections, but it also ignores the literature
that amply demonstrates the contestedness of the con-
cept of health [25].
The recognition that athletes are guinea pigs in an un-
regulated or improper system of research prompts a re-
flection also on another problematic mode of
participation in clinical research, namely healthy volun-
teers who make a living out of participation in Phase 1
studies, mainly but not exclusively in the USA. In the
next section we highlight how, in a similar way to what
happens in the context of professional sports, norms of
research ethics are exacerbated in this new mode of par-
ticipation in research.
Human guinea pigs in the pharmaceutical
industry
In the last few years social scientists have taken an inter-
est in the new realities of ‘professional guinea pig com-
munities’ in the USA [26-30]. Elliott [27] and Abadie
[28] document respectively from an ethical and an an-
thropological point of view the realities of the healthy
individual making a living of participating in one Phase
1 trial after another, or even in more than one Phase 1
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of a new pharmaceutical drug or treatment in a re-
stricted number of patients, after the treatment has
proved efficacious in laboratory testing and animal
models [31]. While in the early ‘90s more than 80% of
industry-sponsored trials were conducted in academic
health settings, by 2005 only 25% of all US clinical trials
were conducted at universities, and this shift away from
an academic setting to a pharmaceutical one is increas-
ing [26]. As the US still conducts about 60% of all clin-
ical trials worldwide, this represents a major change in
the field of clinical research [32].
Who are these ‘professional guinea pigs’? Typically the
population comprises healthy young males in their 20’s
and 30’s who belong to un (der) insured fractions of the
US population, which can be easily recruited by the
pharmaceutical industry into clinical trials in exchange
for payments and limited medical attention during the
study. Payments ranging from $100 to $300 per day are
not uncommon [33]. As noted by Fisher (2009), some of
the participants, being without [sufficient] medical insur-
ance, see participation in clinical trials also as a way of
having access to care [26]. This perception though is a
misperception on their part, as even the limited medical
attention that they may receive during the study is lim-
ited to the physiological parameters, which are a neces-
sary condition for their participation. This perception,
we argue, could be regarded as a ‘variant’ of the wide-
spread phenomenon of ‘therapeutic misconception’ [34]
that characterizes Phase 1 trials. Therapeutic misconcep-
tion arises when subjects misinterpret the primary pur-
pose of a clinical trial as therapeutic, and conflate the
goals of research with the goals of clinical care [34]. By
analogy, we could say that athletes who engage in dop-
ing practice without any evidential basis of the perform-
ance enhancing effects of the substances may also be
victims of a similar phenomenon, which we refer to as
the ‘enhancement’ where they think they are receiving a
benefit (i.e. a performance advantage), while they are
not. What both communities of human guinea pigs are
receiving for sure are health risks. Adverse effects such
as headaches, skin reactions, nausea, and diarrhoea are
very common in Phase 1 trials. More serious risks like
allergic reactions, liver/kidney failure, and severe ar-
rhythmias are rarer, but by no means unique. In limited
cases death is the outcome of research participation
[35]. We noted in Section Multiplicity the non-trivial
health risks that athletes are willing to take in exchange
for the hope of a performance enhancement.
While it may seem difficult to accept that one and the
same participant can be enrolled in multiple trials at the
same time, or successively in one trial after the other,
this practice is made comprehensible by the economic-
ally driven reluctance of pharmaceutical companies toshare information about participants with their rival
companies. Thus, insofar as the volunteers themselves
do not disclose their other commitments and are able to
juggle their schedules, they can be enrolled in more than
one study at a time run by different companies. It is
quite obvious therefore that the current system of clin-
ical research as run by pharmaceutical companies re-
wards a high-risk attitude among serial participants, as it
incentivizes them not to respect the normal wash-out
period of thirty days in order to be enrolled in as many
trials as possible.
In research ethics, ‘vulnerability’ is typically understood
as the participant degree of (in) competence to reach an
autonomous decision regarding participation in clinical
research, after having assessed - free from coercion or
undue influence - the available alternatives [36]. Being
research subjects in an unregulated research system, as
the professional sport context, makes athletes ‘vulner-
able’ subjects, and therefore in need of extra layers of
protection that, as we argue below, would take the form
of a proper framework for research on performance en-
hancing methods and substances. It seems therefore that
serial participants in early pharmaceutical research could
also qualify as vulnerable from a social and economic
point of view [36], and as such would deserve special
protection that they do not currently enjoy. In addition,
participants are incentivized not to disclose any adverse
events they might be experiencing: the burden of proof
to demonstrate the causal link between the clinical trial
participation and the adverse event is on the participant,
and dropping out of a trial compromises the ability of
the individual to remain a serial participant, and jeopar-
dizes the significant financial ‘completion-bonus’.
For these reasons, the practice of serial participation in
Phase 1 trials is seriously problematic from an ethical
point of view, and highlights issues that are present also
in the context of professional sport. Indeed, both the
current system of clinical research as run by pharma-
ceutical companies and of professional sports reward
high-risk behaviour and lack of transparency among ser-
ial participants. Both communities of serial participants
can be considered vulnerable on different - though re-
lated - grounds. Both communities also lack visibility, in
the sense of lack of systemic accountability, due to the
absence of a central regulatory system (in the context of
pharmaceutical research, individuals can participate in
multiple studies run by different companies that do not
share data on their pool of participants), and in the
sense of lack of information that the subjects have on
the substances they are taking, and the procedures to
which they are subjected. Finally, both communities face
a problem of consistency, as the effects of financial in-
centives not to disclose adverse events, not to respect
the required one month wash-out period between trials,
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cloud a precise and proper appreciation for the potential
enhancing effects of the agent and its side effects.
We believe that the combination of these factors ren-
ders near-impossible sound inferences on the effects of
the pharmacological agent, and that a regulated research
system aimed specifically at studying the performance
enhancing effects of agents is urgently needed. To this
problem we now turn.
The need for research on enhancements
The only existing, albeit small, review of the few existing
studies with substances that might enhance athletic per-
formance has been conducted by Maschke (2009) [37],
who points out the tension raised by the necessity to re-
search on the performance enhancing effects of such
agents, together with the necessity to develop accurate
detection tests on the right pool of subjects, and the
legitimization that such necessary research would seem
to impress on the use of doping agents. Green (2009)
further illustrates the point of “externality” (noted in
Section Human guinea pigs in the pharmaceutical indus-
try above), or of the unrepresentativeness of the subjects
of the study [38]. He writes of his participation in a
study aimed at validating testing to detect recombinant
erythropoietin (rHuEPO) (a doping product used to en-
hance speed endurance) before the 2002 Winter Olym-
pics. Green notes that one of the criteria for inclusion of
volunteers in the study was that the subjects could not
be subjected to drug testing, nor actively competing at a
level that would render them a potential subject in a
relevant anti-testing pool (this in accordance with
WADA Code). Under these circumstances, Olympic ath-
letes who commit an anti-doping rule violation (i.e., re-
turn a sample that is positive for substances) could
challenge the validity of the testing, on the basis that the
test was not developed with a representative cohort, and
that somehow Olympic athletes metabolized rHuEPO
differently from untrained individuals [39].
The rHuEPO case should not be understood as an iso-
lated example, as the problem of the reliability of the
extrapolation of data obtained on a pool of healthy vol-
unteers (and in addition, who participate in several trials
at a time, or in one trial after another) to a pool of
elite athletes is much broader, and encompasses all the
doping substances that are on the WADA banned list,
plus the many other agents which may have potential
performance-enhancing effects and that have not been
included yet in the WADA list. As Eynon points out, it
is problematic that: “Much of what we already know on
sports genetics and will learn in the future has to be in-
ferred from studies in non-athletic populations” [39]. In
so far as there is disagreement as to the extent that valid
and reliable methods of detection exist, athletes who testpositive may challenge the scientific validity and reliabil-
ity of results obtained on a different pool of subjects,
with different doses of substance, or not obtained at all.
This contestation speaks directly to the perceived legit-
imacy of anti-doping policy.
Even if we recognize the tension pointed out by
Maschke [37], it does not follow that when one argues
for research on enhancements one thereby legitimizes or
endorses the enhancements one is researching on. Ra-
ther, we hold that an analysis of the ethical permissibility
of research on enhancements should proceed with a
two-tiered strategy, by focusing first on how to justify
such research at a general level, and then on analysing
the ethical permissibility of a particular research on a
case-by-case basis [40]. As to the latter point, what are
these ethical requirements that research on enhance-
ments should fulfill in order to be permissible? It is
commonly accepted that for clinical research to be
ethical, it must fulfill seven individually necessary and
jointly sufficient requirements: It must (1) have health-
related social value, (2) be scientifically valid, (3) use fair
subject selection, (4) involve a favorable risk-benefit ra-
tio, (5) be independently reviewed, (6) satisfy informed
consent requirements, and (7) respect enrolled partici-
pants [41].
How might these requirements translate to research
on enhancements? The translation of criteria (2) to (7)
from a clinical research context to an enhancement
context seems to us to be quite straightforward. On the
contrary, the translation of criterion (1) is not straight-
forward. It is not immediately clear that research on en-
hancement ought to be justified by having health-related
social value, even though there might be some cases of
‘dual use’ biomedical interventions, or interventions that
can be used both as treatments and as enhancements. In
such cases any health-related social value can be seen as
an added value rather than a prerequisite. The health of
the athlete should of course still remain a primary con-
cern (see below for a discussion of the risks/benefits
evaluation), but research on performance enhancing
substances should not have as one of its goal the promo-
tion of health. Its first epistemic goal pertains to the
validity and reliability or otherwise of performance
enhancement claims. Of course this epistemic goal is
framed by an ethical one. Thus the evaluation of risks
and benefits (criterion 4) needs also to be modified when
shifting from the clinical to enhancement contexts. Pre-
cisely what counts as benefit and risk in enhancement
research need not be identical with what counts as bene-
fit and risk in clinical research.
In addition to the criteria spelled out by Emanuel et al.
(2000) for the justification of clinical research [41], it is
necessary to add a criterion of ‘accountability’ to the jus-
tification of enhancement research, both in clinical and
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parency, or visibility using Calvino’s foil, of two practices
of research described in this essay. As illustrated above
by Dressel’s case, the lack of accountability is a wide-
spread problem in professional sport, and the absence of
a central regulation allows and incentivizes high risk be-
haviour of serial participation among health volunteers
in Phase 1 trials.
Let us assume for the moment that research on en-
hancements can be justified from an ethical point of
view at a general level, on the basis of the criteria spelled
out above. To reiterate, we do not argue that this first
level of justification would imply that research on en-
hancements tout court would also be justified: individual
cases would still need to be reviewed and justified –or
not – on a case-by-case basis. Indeed, there has been
considerable disquiet in the anti doping policy world
about the adequacy of the evidential basis (or lack
thereof ) that WADA use to base their decisions for in-
clusion of substances and methods (i.e., what constitutes
doping) on their Prohibited List. During the recent sec-
ond revision of the WADA CODE, there was consider-
able support to alter the criteria for choosing items on
the prohibited methods and substance list (what most
people understand to be designated by the term ‘dop-
ing’). Revisionists argued that the 2015 WADA CODE
should elevate ‘performance enhancement’ from being
merely one of three defeasible criteria to the sole neces-
sary condition of doping, to be supported by either of
both of the remaining (now) secondary conditions: ‘(po-
tential) harm to health’ and ‘(potential) contrariness to
the spirit of sport’ [25]. This would increase the visibility
of the substances in the Prohibited List, which at
present, are not (or at least often not) supported by high
quality evidential bases [37]. Indeed, many of the sub-
stances included in the Prohibited List are merely pre-
sumed to be ergogenic, and have not been subjected to
rigorous, randomized controlled studies, or if they have,
that was done in a different pool of subjects than those
who are effectively going to take the substances.
The inclusion of the performance enhancement criter-
ion as a necessary condition in the revised 2015 WADA
CODE was widely supported during the revision process,
and yet it was rejected in the final version of the revised
CODE. Nevertheless, if the performance enhancing cri-
terion indeed were to have become a necessary condi-
tion, there would need to be reasonable grounds for a
substance’s or method’s inclusion on the Prohibited List
– reasonable grounds that, at the moment, do not ap-
pear to be evident. Therefore, we have argued in this
paper that a proper governance framework needs to be
established, both to assess the performance enhancing
effects of the substances, and the risks of harm to the
health of the athlete. We note here the problematicnature of the ‘potential risk to the health of the athlete’
criterion, which, contrary to the potentiality of the per-
formance enhancing effect, has not been under discus-
sion in the Code revision process. Further discussion of
this problem is beyond the scope of the present essay
(see instead [25]).
We do not, by any means, argue in favour of WADA
suspending their enforcement power until a certain
point in the future is reached when the performance en-
hancing effects of each of the substances or methods on
the Prohibited List is demonstrated. We argue instead
that the inclusion of the substances in the List should
proceed following the precautionary principle [42],
though it should not be used indiscriminately [43], but
only where there are reasonable grounds to infer a per-
formance enhancing effect, or risk to the harm of the
athletea. Sometimes this will involve reasonable extrapo-
lation. For instance, there is good evidence to suggest
that the use of beta-blockers enhances performance in
pistol shooting [44] and that this might be contrary to
the spirit of sport. Thus beta-blockers are banned. Yet
the ban applies not only to target sports - where the in-
ference is reasonable - but also to other sports including
Formula 1 style motor racing, skiing and snowboarding,
where its performance enhancing effects seem less than
obvious. To be clear, we would not count as reasonable
grounds anecdotal evidence on performance enhancing
effects or harmful effects a substance, such as creatine
with (say) a particular population (children).
We know as a matter of fact that elite athletes will take
risks. A century ago that would have included the use of
strychnine [45] in what we referred to as the enhancement
and a more scientific approach to performance enhance-
ment may well have fueled the use of growth hormones
[46,47]. Yet, the precise enhancing effects here are not
clear. Is the inference so obvious that it invokes the pre-
cautionary principle? Probably: but transparency would
require a reasonable and public statement of the principle.
Sadly, WADA have not hitherto been minded to operate
in this way and we suggest that compliance and concord-
ance with the WADA Code might follow upon greater
visibility as to their decision-making.
Conclusions
As noted by King and Robeson (2007) [8], the transla-
tion of norms of medical ethics to sport medicine with-
out their re-visioning can be problematic. The clash
of interests in sports medicine between services to
the athlete-patient and the contracting party is well
known [3], but discussions are more frequently framed
in terms of return to play issues or enhanced recovery.
In this paper we have focused on the relatively unex-
plored nexus of medical ethics, research ethics and
sport medicine, using as a case study two communities
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As our analysis has shown, both doping and phase 1
trial scenarios are similar in the multiplicity of the drugs
that the individual is simultaneously taking; the lack of
visibility (in the sense of transparency and accountability)
of the context; and the high level of risks the individuals
engaged in these practices are taking onto themselves.
The benefits expected for the participants differ in nature
and magnitude, but the risks both communities are en-
gaging in are clear. Both scenarios also pose a problem of
consistency both in regard to the application of the trial
guidelines, and of the value of the data that are extrapo-
lated from such research. Thus, both categories - although
for different reasons- can be considered vulnerable and
worthy of special protection through the establishment of
a proper governance framework for regulation of research.
The practice of professional guinea pigs in Phase 1 trials
represents an issue of exploitation of economically vulner-
able subjects in a developed society (USA) that has allowed
the pursuit of medical and scientific knowledge to move
away from an academic setting to a pharmaceutical indus-
try concerned only with profit and that, under a rhetoric of
participation and progress, exposes the individuals to a
multiplicity of agents whose interactions are unknown and
impossible to infer, in exchange for a limited paycheck
whose payment schedule incentivises high-risk behavioursb.
Returning to Calvino’s foil and the context of profes-
sional sports, we propose the legitimization of a research
enterprise to measure the enhancement effects of agents
within a systematic governance framework. This would
promote greater visibility and consistency in the context
of professional sport currently lacking both, and where
athletes may be subjected to an unregulated research
system, which poses high risks to their health. This
might also substantially increase the visibility of the sub-
stances in the Prohibited List, which at present are not
(or at least mostly not) supported by high quality evi-
dential bases. If the performance enhancing criterion
were to become a necessary condition in a subsequent
version of the WADA Code, then there must be greater
justification and transparency concerning the grounds
for the inclusion of substances in the Prohibited List.
There also need to be reasonable evidence that the sub-
stance is harmful to health as opposed to an indiscrimin-
ate use of the precautionary principle.
As for multiplicity, it is a feature of our millennium
that we regard as impossible and undesirable to be rid
of. Nevertheless we can, and should, devise better ways
to navigate it.
Endnotes
aThis blanket application of the precautionary
principle is evidenced by WADA’s category of NonApproved substances. Prior to specifying particular prod-
ucts or processes they write: “Any pharmacological sub-
stance which is not addressed by any of the subsequent
sections of the List and with no current approval by any
governmental regulatory health authority for human
therapeutic use (e.g. drugs under pre-clinical or clinical
development or discontinued, designer drugs, substances
approved only for veterinary use) is prohibited at all
times.” [http://list.wada-ama.org/prohibited-in-competition/
prohibited-substances/] Accessed 31.10.2013.
bRather, we believe that the pursuit of medical and sci-
entific knowledge should not solely be left in the hands of
the pharmaceutical industry, but we cannot pursue this
line of inquiry in depth here. We refer to Fisher for an
insightful analysis of the economic, social and political mi-
lieux of the shift from research conducted within the aca-
demic realm to the private sector [26].
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